

參 考 文 獻

Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J (1996) Human ICE/CED-3 protease nomenclature. *Cell* **87**, 171.

Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. *J Natl Cancer Inst* **93**, 1375-84.

Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. *Cancer Res* **58**, 2825-31.

Bateman JC (1955) Cancer chemotherapy. *Med Ann Dist Columbia* **24**, 55-62.

Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sakhmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. *Cancer* **98**, 1802-10.

Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. *Nature* **411**, 355-65.

Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ (2003) Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis. *Oncogene* **22**, 6679-89.

Buckley CD, Pilling D, *et al.* (1999) RGD peptides induce apoptosis by direct caspase-3 activation. *Nature* **397**, 534-9.

Chen L, Jin J, Davis J, Zhou Y, Wang Y, Liu J, Lockhart PJ, Zhang J (2007) Oligomeric alpha-synuclein inhibits tubulin polymerization. *Biochem Biophys Res Commun* **356**, 548-53.

Chen X, Plasencia C, Hou Y, Neamati N (2005) Synthesis and biological evaluation

of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. *J Med Chem* **48**, 1098-106.

Chlebowski RT, Col N, *et al.* (2002) American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. *J Clin Oncol* **20**, 3328-43.

Ciardello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. *Clin Cancer Res* **7**, 2958-70.

Ciocca DR, Gago FE, Fanelli MA, Calderwood SK (2006) Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. *J Steroid Biochem Mol Biol* **102**, 32-40.

Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M (2007) Progress and new standards of care in the management of HER-2 positive breast cancer. *Eur J Cancer* **43**, 497-509.

Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature* **391**, 43-50.

Fadeel B, Orrenius S (2005) Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. *J Intern Med* **258**, 479-517.

Furuuchi K, Berezov A, Kumagai T, Greene MI (2007) Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. *J Immunol* **178**, 1021-9.

Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Garcia-Escudero A, Pareja Megia MJ, Montironi R, Lopez-Beltran A (2007) BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. *Cancer Lett* **250**, 292-9.

Harari PM, Huang SM (2000) Modulation of molecular targets to enhance radiation. *Clin Cancer Res* **6**, 323-5.

Harms JF, Welch DR, *et al.* (2004) A small molecule antagonist of the alpha(v)beta3

- integrin suppresses MDA-MB-435 skeletal metastasis. *Clin Exp Metastasis* **21**, 119-28.
- Hartmann K, Wagelie-Steffen AL, von Stebut E, Metcalfe DD (1997) Fas (CD95, APO-1) antigen expression and function in murine mast cells. *J Immunol* **159**, 4006-14.
- Herrup K, Yang Y (2007) Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? *Nat Rev Neurosci* **8**, 368-78.
- Ho A, Dowdy SF (2002) Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. *Curr Opin Genet Dev* **12**, 47-52.
- Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH (1999) Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? *Clin Cancer Res* **5**, 3645-52.
- Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. *Cancer Res* **48**, 7022-32.
- Jayaprakasam B, Seeram NP, Nair MG (2003) Anticancer and antiinflammatory activities of cucurbitacins from *Cucurbita andreana*. *Cancer Lett* **189**, 11-6.
- Jenny M, Schwaiger W, Bernhard D, Wrulich OA, Cosaceanu D, Fuchs D, Ueberall F (2005) Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2. *J Carcinog* **4**, 15.
- Jiang S, Li P, Peach ML, Bindu L, Worthy KW, Fisher RJ, Burke TR, Jr., Nicklaus M, Roller PP (2006) Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. *Biochem Biophys Res Commun* **349**, 497-503.
- Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T (2005) Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. *Crit Rev Oncol Hematol* **53**, 35-69.
- Jonat W (2002) Role of LHRH agonists in premenopausal women with oestrogen

receptor-positive breast cancer: the ZEBRA experience. *Eur J Cancer* **38 Suppl 6**, S39-40.

Kameda K, Kondo T, Tanabe K, Zhao QL, Seto H (2001) The role of intracellular Ca(2+) in apoptosis induced by hyperthermia and its enhancement by verapamil in U937 cells. *Int J Radiat Oncol Biol Phys* **49**, 1369-79.

Kim TI, Tchah H, Lee SA, Sung K, Cho BJ, Kook MS (2003) Apoptosis in keratocytes caused by mitomycin C. *Invest Ophthalmol Vis Sci* **44**, 1912-7.

Kunitomo K, Inoue S, Ichihara F, Kono K, Fujii H, Matsumoto Y, Ooi A (2004) A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. *Hum Pathol* **35**, 379-81.

Lau KM, LaSpina M, Long J, Ho SM (2000) Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. *Cancer Res* **60**, 3175-82.

Li P, Li Y, Li JY, Liu J (2003) Characterization and utilization of two novel anti-erbB-2 monoclonal antibodies in detection of soluble ErbB-2 for breast cancer prognosis. *Cancer Lett* **193**, 139-48.

Lindgren M, Rosenthal-Aizman K, Saar K, Eiriksdottir E, Jiang Y, Sassian M, Ostlund P, Hallbrink M, Langel U (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. *Biochem Pharmacol* **71**, 416-25.

Lundberg AS, Weinberg RA (1999a) Control of the cell cycle and apoptosis. *Eur J Cancer* **35**, 1886-94.

Lundberg AS, Weinberg RA (1999b) Control of the cell cycle and apoptosis. *Eur J Cancer* **35**, 531-9.

Lung FD, Chang CW, Chong MC, Liou CC, Li P, Peach ML, Nicklaus MC, Lou BS, Roller PP (2005) Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology. *Biopolymers* **80**, 628-35.

- Lung FD, Tsai JY (2003) Grb2 SH2 domain-binding peptide analogs as potential anticancer agents. *Biopolymers* **71**, 132-40.
- Lung FD, Tsai JY, Wei SY, Cheng JW, Chen C, Li P, Roller PP (2002) Novel peptide inhibitors for Grb2 SH2 domain and their detection by surface plasmon resonance. *J Pept Res* **60**, 143-9.
- Mandal S, Berube G, Asselin E, Richardson VJ, Church JG, Bridson J, Pham TN, Pramanik SK, Mandal SK (2007) A new platinum complex of triazine demonstrates G1 arrest with novel biological profile in human breast cancer cell line, MDA-MB-468. *Bioorg Med Chem Lett* **17**, 2139-45.
- Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, Nakachi K, Gustafsson JA, Hayashi S (2002) Estrogen receptor beta is expressed in human stomach adenocarcinoma. *J Cancer Res Clin Oncol* **128**, 319-24.
- McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. *Bmj* **321**, 624-8.
- Mehmet H (2000) Caspases find a new place to hide. *Nature* **403**, 29-30.
- Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. *FEBS Lett* **392**, 49-53.
- Niewolik D, Vojtesek B, Kovarik J (1995) p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. *Oncogene* **10**, 881-90.
- Nunez G, Benedict MA, Hu Y, Inohara N (1998) Caspases: the proteases of the apoptotic pathway. *Oncogene* **17**, 3237-45.
- Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochim Biophys Acta* **1602**, 73-87.
- Rao L, Perez D, White E (1996) Lamin proteolysis facilitates nuclear events during apoptosis. *J Cell Biol* **135**, 1441-55.
- Ruoslahti E (2003) The RGD story: a personal account. *Matrix Biol* **22**, 459-65.

- Ryan KM, Birnie GD (1996) Myc oncogenes: the enigmatic family. *Biochem J* **314** (Pt 3), 713-21.
- Shadidi M, Sioud M (2003) Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. *Faseb J* **17**, 256-8.
- Shi ZD, Lee K, *et al.* (2003) A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. *Biochem Biophys Res Commun* **310**, 378-83.
- Skolnik EY, Lee CH, *et al.* (1993) The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. *Embo J* **12**, 1929-36.
- Sommer S, Fuqua SA (2001) Estrogen receptor and breast cancer. *Semin Cancer Biol* **11**, 339-52.
- Song YL, Peach ML, Roller PP, Qiu S, Wang S, Long YQ (2006) Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives. *J Med Chem* **49**, 1585-96.
- Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. *Cancer Res* **62**, 2141-50.
- Stacey NH, Bishop CJ, Halliday JW, Halliday WJ, Cooksley WG, Powell LW, Kerr JF (1985) Apoptosis as the mode of cell death in antibody-dependent lymphocytotoxicity. *J Cell Sci* **74**, 169-79.
- Stennicke HR, Salvesen GS (1998) Properties of the caspases. *Biochim Biophys Acta* **1387**, 17-31.
- Thriveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G (2007) Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. *Indian J Med Res* **125**, 137-42.

Tyson JJ, Novak B, Odell GM, Chen K, Thron CD (1996) Chemical kinetic theory: understanding cell-cycle regulation. *Trends Biochem Sci* **21**, 89-96.

Vazquez-Martin A, Colomer R, Menendez JA (2007) Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. *Eur J Cancer* **43**, 1117-24.

Wiegratz I, Kuhl H (2004) Progestogen therapies: differences in clinical effects? *Trends Endocrinol Metab* **15**, 277-85.

Wolf BB, Green DR (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. *J Biol Chem* **274**, 20049-52.

Zhang JH, Xu M (2000) DNA fragmentation in apoptosis. *Cell Res* **10**, 205-11.

Zitzmann S, Ehemann V, Schwab M (2002) Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. *Cancer Res* **62**, 5139-43.

94 年衛生統計動向，行政院衛生署統計室發行

瞿中和，王喜中，丁明孝 (2001) 細胞分子生物學，九州圖書文物有限公司。